Inovio wins US patent for cervical dysplasia, cancer vaccine
The patent covers Inovio’s synthetic consensus HPV antigens, DNA constructs and vaccines that include these antigens, including VGX-3100, cervical dysplasia/cancer vaccine. The methods used for treating patients with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.